Other Information
+Added: Deferred 2023 bonuses of $500,000 were paid in May 2024 to Thomas Equels for $350,000 and Peter Rodino for $150,000.
- See exhibit index below.
−Removed: Certificate of Increase of Series A Junior Participating Preferred Stock (incorporated by reference to exhibit 3.1 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended March 31, 2023).
−Removed: Amended and Restated By-Laws of Registrant (incorporated by reference to exhibit 3.7(ii) to the Company’s Annual report on Form 10-K (No.
−Removed: 001-27072) for year ended December 31, 2022).
+Added: Certificate of Increase of Series A Junior Participating Preferred Stock.
+Added: (incorporated by reference to exhibit 3.1 to the Company’s Quarterly report on Form 10-Q (No.
+Added: 001-27072) for the year ended March 31, 2023).
Third Amended and Restated Rights Agreement, dated May 12, 2023 between AIM ImmunoTech Inc.
3 unchanged sentences
001-27072) filed May 15, 2023).
−Removed: June 27, 2022 First Amendment to Agreement of Sale and Purchase with Acellories, Inc.
−Removed: (incorporated by reference to exhibit 10.86 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended June 30, 2022).
−Removed: August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc.
−Removed: (incorporated by reference to exhibit 10.87 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended June 30, 2022).
−Removed: October 5, 2022 Lease extension for Riverton office (incorporated by reference 10.4 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended September 30, 2022 filed November 14, 2022).
−Removed: October 11, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.5 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended September 30, 2022 filed November 14, 2022).
−Removed: October 21, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.6 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended September 30, 2022 filed November 14, 2022).
−Removed: October 21, 2022 Fourth Amendment to Agreement of Sale and Purchase with Acellories, Inc (incorporated by reference 10.7 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended September 30, 2022 filed November 14, 2022).
−Removed: 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc.
−Removed: (incorporated by reference 10.93
−Removed: to the Company’s Annual report on Form 10-K (No.
−Removed: 001-27072) for year ended December 31, 2022).
−Removed: January 13, 2023 Study Support Agreement with Erasmus University Medical Center Rotterdam (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.94 to the Company’s Annual report on Form 10-K (No.
−Removed: 001-27072) for year ended December 31, 2022).
−Removed: January 13, 2023 Co-ordination Agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.95 to the Company’s Annual report on Form 10-K (No.
−Removed: 001-27072) for year ended December 31, 2022).
−Removed: March 1, 2023 Extension Agreement with Foresite Advisors LLC (incorporated by reference 10.96 to the Company’s Annual report on Form 10-K (No.
−Removed: 001-27072) for year ended December 31, 2022).
−Removed: April 4, 2023 Unrestricted Grant Agreement with Erasmus University Medical Center (incorporated by reference to exhibit 10.1 to the Company’s Current Report on Form 8-K (No.
−Removed: 001-27072) filed April 7, 2023).
−Removed: April 5, 2023 Independent Contractor Service Agreement with Casper H.J van Eijck (incorporated by reference to exhibit 10.2 to the Company’s Current Report on Form 8-K (No.
+Added: February 16, 2024 Note Purchase Agreement with Streeterville Capital LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (No.
+Added: 001-27072) filed February 20, 2024).
+Added: February 16, 2024 Promissory Note with Streeterville Capital LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (No.
+Added: 001-27072) filed February 20, 2024).
+Added: Atlas Equity Purchase Agreement (incorporated by reference to Exhibit 10.104 to the Company’s annual report on Form 10-K (No.
+Added: 001-27072) for the year ended December 31, 2023).
+Added: Atlas Registration Rights Agreement (incorporated by reference to Exhibit 10.104 to the Company’s annual report on Form 10-K (No.
+Added: 001-27072) for the year ended December 31, 2023).
+Added: October 4, 2023 Lease extension for Riverton office (incorporated by reference to Exhibit 10.106 to the Company’s Registration Statement on Form S-1 (No.
333-278839) filed April 19, 2024).
−Removed: April 19, 2023 Equity Distribution Agreement with Maxim Group, LLC (incorporated by reference to exhibit 10.2 to the Company’s Current Report on Form 8-K (No.
+Added: March 15, 2024 Addendum 1 to Lease for Ocala office (incorporated by reference to Exhibit 10.107 to the Company’s Registration Statement on Form S-1 (No.
333-278839) filed April 19, 2024).
−Removed: Material Transfer and Research Agreement, dated as of May 22, 2023, with Japanese National Institute of Infectious Disease (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to 10.1 to the Company’s Current Report on Form 8-K (No.
−Removed: 001-27072) filed May 30, 2023).
−Removed: September 20, 2023 Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (incorporated by reference to Exhibit 10.1 to the Company’s Current Report of Form 8-K (No.
−Removed: 001-27072) filed September 29, 2023).
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.
2 unchanged sentences
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Schema
−Removed: XBRL Taxonomy Calculation Linkbase
−Removed: XBRL Taxonomy Definition Linkbase
−Removed: XBRL Taxonomy Label Linkbase
−Removed: XBRL Taxonomy Presentation Linkbase
−Removed: Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
4 unchanged sentences
Financial Officer
−Removed: November 14, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.